Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fingolimod for acute ischemic stroke
IRCT20250424065459N1Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke comparing Fingolimod plus standard treatment with Placebo plus standard treatment (2 arms). Primary endpoint: National Institutes of Health Stroke Scale score. Started Sep 2025; status: completed.
02
Drugs
fingolimod
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on IRCT20250424065459N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250424065459N1.